Expert Interview
A Third Look: Discussing the results from the 52-week data from the Phase 2b VOYAGE Study of VK2809, a liver-selective thyroid hormone receptor beta agonist, in patients with NASH.
Ticker(s): VKTXInstitution: St. Joseph Hospital
- A board-certified gastroenterology/hepatology attending physician.
- Clinical interests include Focus on : Inflammatory bowel disease (ulcerative colitis and Crohn's disease), endoscopy/colonoscopy/capsule endoscopy, gastrointestinal technology, GI bleed, abdominal pain, peptic ulcer disease, celiac disease, irritable bowel syndrome, functional problems, dysphagia, gastritis, duodenitis, viral hepatitis, fatty liver disease, alcoholic liver disease, cirrhosis, other hepatitis, genetic liver disease ischemic liver and drug induced liver injury.
- Currently manages 65 NASH patients; 50 patients with HBV
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
